Challenges for drug discovery and development in China

Area of Science:

• Pharmacology and Drug Development
• Traditional Chinese Medicine Research
• Biomarker Discovery

Background:

• The global drug development landscape is undergoing significant restructuring.
• China faces substantial hurdles in drug discovery and development, mirroring challenges seen in Western pharmaceutical industries.
• Proprietary Chinese Medicines (pCM) are a popular therapeutic strategy for chronic diseases, including allergic conditions like eczema, asthma, and allergic rhinitis.

Purpose of the Study:

• To review contemporary therapeutic strategies in China, focusing on anti-cancer, anti-allergy, anti-infectious agents, and pCM.
• To highlight key research technologies such as drug transporters, disease-specific biomarkers, pharmacophores, bioactive natural products, and pharmacogenetics.
• To discuss factors impacting drug development in China and propose solutions for improved monitoring and evaluation.

Main Methods:

• Literature review of anti-cancer, anti-allergy, anti-infectious, and proprietary Chinese medicines.
• Analysis of research technologies including drug transporters, biomarkers, pharmacophores, natural products, and pharmacogenetics.
• Discussion of challenges and expert opinions on drug development in China's complex healthcare system.

Main Results:

• Proprietary Chinese Medicine (pCM) is a prevalent strategy, but robust documentation of efficacy versus adverse effects remains a concern.
• Key research areas include drug transporters, disease biomarkers, pharmacophores, natural products, and pharmacogenetics.
• Concurrent use of Western and Chinese medicines, pharmacogenetic variations, and multidisciplinary team limitations impact drug development and safety.

Conclusions:

• China's drug development faces unique challenges due to its healthcare system and the integration of traditional and Western medicine.
• Implementing big data analysis, similar to the UK and US, can centralize data for enhanced drug monitoring, clinical evaluation, and cost-effective healthcare.
• Further research is needed to ensure the documented efficacy and safety of proprietary Chinese medicines.